The group’s principle activity is to provide pharmaceutical drug discovery and design services. The group’s drug discovery programs include therapies for cancer, cardiovascular disorders and diabetes. The group’s products include DPP IV inhibitor for type II diabetes, and reverse D-4F, an orally active apo A-I mimetic peptide for the treatment of atherosclerosis. The group operates from United States.
